Regeneron Pharmaceuticals Inc (MIL:1REGN)
€ 757 -25.2 (-3.22%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 79/100

Regeneron Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 12:45PM GMT
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Regeneron with us for the next session.

I just need to read a disclosure statement before we begin. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

And very pleased to have Marion McCourt, who runs commercial; and Justin Holko, who runs IR, with us. I'm going to turn it over to them to make some opening comments, and then we can jump into Q&A.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Great. Thank you, Matthew. Great opportunity to be with you again this year.

Before we begin, I would like to remind you that remarks made today forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot